cpg-4 Antibody
Description
Definition and Composition of CpG-4 Antibody
The term "CpG-4 Antibody" refers to a combination therapeutic strategy involving CpG oligodeoxynucleotide (CpG-ODN) and anti-4-1BB monoclonal antibody. This approach synergistically enhances antitumor immune responses by activating innate and adaptive immunity .
-
CpG-ODN: A synthetic DNA sequence containing unmethylated cytosine-guanine motifs that activate Toll-like receptor 9 (TLR9) on dendritic cells (DCs) and B cells, promoting pro-inflammatory cytokine production and DC maturation .
-
Anti-4-1BB Antibody: Targets the 4-1BB co-stimulatory receptor (CD137) on activated T cells and DCs, amplifying T cell proliferation, survival, and cytotoxic activity .
Mechanism of Action
The combination exerts antitumor effects through dual immunomodulatory pathways:
Immune Activation Pathways
| Component | Target Cells | Mechanism | Outcome |
|---|---|---|---|
| CpG-ODN | Dendritic cells, B cells | TLR9 activation → IL-12/IFN-γ secretion ↑ | Enhanced antigen presentation |
| Anti-4-1BB Antibody | CD8+ T cells, DCs | 4-1BB ligation → T cell proliferation ↑ | Tumor-specific cytotoxicity amplification |
This dual activation reduces immunosuppressive Tregs while increasing CD8+ T cell infiltration into tumors .
Tumor Growth Inhibition
In a hepatocellular carcinoma (HCC) mouse model, CpG-ODN + anti-4-1BB antibody:
Immune Biomarker Changes
| Parameter | CpG-ODN Alone | Anti-4-1BB Alone | Combination Therapy |
|---|---|---|---|
| Serum IL-12 (pg/mL) | 120 ± 15 | 105 ± 12 | 280 ± 25 |
| CD8+ T Cells (%) | 18 ± 2 | 22 ± 3 | 35 ± 4 |
| Tregs (%) | 12 ± 1 | 10 ± 1 | 5 ± 0.8 |
Data from spleen and tumor microenvironments showed enhanced cytotoxic T lymphocyte (CTL) activity (2.5-fold increase in tumor cell lysis) .
Synergy with Existing Therapies
-
Combined with BRAF inhibitors in melanoma models, anti-4-1BB antibodies delay drug resistance by sustaining T cell activation .
-
CpG-ODN enhances DC-mediated cross-presentation of tumor antigens, improving checkpoint inhibitor efficacy .
Challenges and Future Directions
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
